+92 300 859 4219 , +92 300 859 1434 
Cash On Delivery is Available
Pfizer stated on Monday its COVID-19 vaccine offered sturdy long-term safety in opposition to the virus in a late-stage examine carried out amongst adolescents aged 12 to fifteen years.
A two-dose collection of the vaccine was 100% efficient in opposition to COVID-19, measured seven days by way of over 4 months after the second dose, the corporate stated.
The long-term knowledge will help deliberate submissions for full-regulatory approval of the vaccine within the age group in the USA and worldwide.
Pfizer and BioNTech will search clearance for a 30 micrograms dose of the vaccine for these aged 12 and above.
The vaccine was licensed for emergency use in individuals aged 12-15 years by the U.S. Meals & Drug Administration in Could, and granted full approval to be used in individuals aged 16 and above in August.
